Summary of the II International Symposium on Cytomegalovirus

被引:139
作者
de Jong, MD
Galasso, GJ
Gazzard, B
Griffiths, PD
Jabs, DA
Kern, ER
Spector, SA
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Clin Virol, NL-1105 AZ Amsterdam, Netherlands
[2] NIH, Bethesda, MD 20892 USA
[3] Chelsea & Westminster Hosp, Dept HIV GUM, London, England
[4] Royal Free Hosp, Sch Med, Communicable Dis Div, London, England
[5] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA
[6] Univ Calif San Diego, Dept Pediat, Div Infect Dis, La Jolla, CA 92093 USA
[7] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA
[8] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
关键词
human cytomegalovirus; diagnosis; treatment; prophylaxis;
D O I
10.1016/S0166-3542(98)00044-8
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Human cytomegalovirus (HCMV) is a highly species-specific DNA virus belonging to the Betaherpesvirinae subfamily of the herpesviridae family. Like other herpesviruses, primary infection with HCMV is followed by persistence of the virus in a latent form. The sites of latency are still largely undefined, but they probably include bone marrow progenitor cells and peripheral blood monocytes. From these sites, the virus can reactivate, resulting in renewed shedding of the virus, or, in immunocompromized persons, development of disease. Humans are the only reservoir of HCMV and transmission occurs by person-to-person contact. Infection with HCMV is common. In most developed countries, HCMV seroprevalence steadily increases after infancy and 10-20% of children are infected before puberty. In adults, the prevalence of antibodies ranges from 40 to 100%. Although HCMV has a world-wide distribution, infection with HCMV is more common in the developing countries and in areas of low socioeconomic conditions, which is predominantly related to the closeness of contacts within these populations. Except for a mononucleosis-like illness in some persons, infection with HCMV rarely causes disease in immunocompetent individuals. However, HCMV can cause severe morbidity and mortality in congenitally infected newborns and immunocompromized patients, most notably transplant-recipients and HIV-infected persons. This article provides a review of the information presented at the Second International Symposium on Cytomegalovirus organized and convened by The Macrae Group (New York City, NY) in Acapulco, Mexico on 24-28 April 1998. During this symposium, the stale-of-the-art knowledge on diagnosis, treatment and prophylaxis of HCMV infections were discussed, and, based on this information, attempts to highlight the future directions in basic and clinical research areas that need to be stimulated to facilitate advancement in prevention and treatment of CMV disease. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:141 / 162
页数:22
相关论文
共 129 条
[1]
IMMUNITY INDUCED BY PRIMARY HUMAN CYTOMEGALOVIRUS-INFECTION PROTECTS AGAINST SECONDARY INFECTION AMONG WOMEN OF CHILDBEARING AGE [J].
ADLER, SP ;
STARR, SE ;
PLOTKIN, SA ;
HEMPFLING, SH ;
BUIS, J ;
MANNING, ML ;
BEST, AM .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (01) :26-32
[2]
Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient [J].
Alain, S ;
Honderlick, P ;
Grenet, D ;
Stern, M ;
Vadam, C ;
SansonLePors, MJ ;
Mazeron, MC .
TRANSPLANTATION, 1997, 63 (10) :1533-1536
[3]
Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA [J].
Anderson, KP ;
Fox, MC ;
BrownDriver, V ;
Martin, MJ ;
Azad, RF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2004-2011
[4]
[Anonymous], 1996, Arch Ophthalmol, V114, P23
[5]
INTRAVITREOUS AND PLASMA-CONCENTRATIONS OF GANCICLOVIR AND FOSCARNET AFTER INTRAVENOUS THERAPY IN PATIENTS WITH AIDS AND CYTOMEGALOVIRUS RETINITIS [J].
AREVALO, JF ;
GONZALEZ, C ;
CAPPARELLI, EV ;
KIRSCH, LS ;
GARCIA, RP ;
QUICENO, JI ;
CONNOR, JD ;
GAMBERTOGLIO, J ;
BERGERONLYNN, G ;
FREEMAN, WR .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (04) :951-956
[6]
The role of antibody concentration and avidity in antiviral protection [J].
Bachmann, MF ;
Kalinke, U ;
Althage, A ;
Freer, G ;
Burkhart, C ;
Roost, HP ;
Aguet, M ;
Hengartner, H ;
Zinkernagel, RM .
SCIENCE, 1997, 276 (5321) :2024-2027
[7]
Badley A D, 1996, Liver Transpl Surg, V2, P375, DOI 10.1002/lt.500020508
[8]
Prophylaxis of cytomegalovirus infection in liver transplantation - A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir [J].
Badley, AD ;
Seaberg, EC ;
Porayko, MK ;
Wiesner, RH ;
Keating, MR ;
Wilhelm, MP ;
Walker, RC ;
Patel, R ;
Marshall, WF ;
DeBernardi, M ;
Zetterman, R ;
Steers, JL ;
Paya, CV .
TRANSPLANTATION, 1997, 64 (01) :66-73
[9]
Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS [J].
Baldanti, F ;
Underwood, MR ;
Stanat, SC ;
Biron, KK ;
Chou, SW ;
Sarasini, A ;
Silini, E ;
Gerna, G .
JOURNAL OF VIROLOGY, 1996, 70 (03) :1390-1395
[10]
A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL ACYCLOVIR FOR THE PREVENTION OF CYTOMEGALO-VIRUS DISEASE IN RECIPIENTS OF RENAL-ALLOGRAFTS [J].
BALFOUR, HH ;
CHACE, BA ;
STAPLETON, JT ;
SIMMONS, RL ;
FRYD, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (21) :1381-1387